| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-04-20 | tenofovir alafenamide (TAF) | hepatitis B | 3 | Gilead Sciences (USA - CA) | Infectious diseases |
| 2017-04-20 | NV556 | NASH (non-alcoholic steatohepatitis) | preclinical | Neurovive Pharmaceutical (Sweden) | Liver diseases - Hepatic diseases |
| 2017-04-19 | Prostvac® (rilimogene), in combination treatment with Yervoy® (ipilimumab) and/or Opdivo® (nivolumab) | localized prostate cancer | 2 | Bavarian Nordic (Denmark) BMS (USA - NY) | Cancer - Oncology |
| 2017-04-19 | Ocaliva® (obeticholic acid - OCA) | primary biliary cirrhosis, primary biliary cholangitis | 3 | Intercept Pharmaceuticals (USA - NY) | Autoimmune diseases- Liver diseases - Hepatic diseases |
| 2017-04-18 | burosumab - recombinant human monoclonal IgG1 antibody for fibroblast growth factor 23/KRN23 | X-linked Hypophosphatemia | 3 | Ultragenyx Pharmaceutical (USA - CA) Kyowa Hakko Kirin (Japan) | Rare diseases - Genetic diseases - Metabolic diseases |
| 2017-04-18 | pegunigalsidase alfa (PRX-102 - alpha-galactosidase-A) | Fabry disease | preclinical | Protalix BioTherapeutics (Israel) | Rare diseases - Genetic diseases |
| 2017-04-17 | elobixibat | chronic constipation | 2 | Albireo Pharma (USA - MA) Albireo (Sweden) EA Pharma (Japan) | Gastrointestinal diseases - Digestive diseases |
| 2017-04-11 | compounds targeting Zika virus | Zika virus infection | preclinical | Abivax (France) | Infectious diseases |
| 2017-04-11 | 4SC-202 | preclinical | 4SC (Germany) | Cancer - Oncology | |
| 2017-04-11 | lefamulin (BC 3781) | community-acquired bacterial pneumonia (CABP) | 3 | Nabriva Therapeutics (Austria) | Infectious diseases |
| 2017-04-11 | INO-4201 | Ebola fever | 1 | Inovio Pharmaceuticals (USA - PA) | Infectious diseases |
| 2017-04-10 | IVA337 - lanifibranor - 1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid) | systemic sclerosis | 2 | Inventiva Pharma (France) | Rare diseases - Autoimmune diseases |
| 2017-04-10 | demcizumab | first-line metastatic pancreatic cancer | 2 | OncoMed Pharmaceuticals (USA - CA) Celgene (USA - NJ) | Cancer - Oncology |
| 2017-04-07 | fruquintinib | non-small cell lung cancer (NSCLC), renal cell cancer | preclinical | Hutchison China MediTech Limited "ChiMed" (China) | Cancer - Oncology |
| 2017-04-07 | sulfatinib | preclinical | Hutchison China MediTech Limited "ChiMed" (China) | Cancer - Oncology | |
| 2017-04-06 | ACH-4471 | paroxysmal nocturnal hemoglobinuria (PNH) | 2 | Achillion Pharmaceuticals (USA - CT) | Rare diseases - Immunological diseases |
| 2017-04-06 | ASN120290 (formerly known as ASN-561) | dementia | 1 | Asceneuron (Switzerland) | CNS diseases - Neurodegenerative diseases |
| 2017-04-05 | TAK-003 (live-attenuated tetravalent dengue vaccine candidate) | dengue fever | 3 | Takeda Pharmaceutical (Japan) | Infectious diseases |
| 2017-04-05 | filgotinib | psoriatic arthritis | 2 | Galapagos (Belgium) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2017-04-05 | Botox® (onabotulinumtoxinA) | major depressive disorder (MDD) | 2 | Allergan (Ireland) | CNS diseases - Mental diseases |
